Evolving Strategies for the Management of Fecal Incontinence

Rebecca A. Levine, MD Assistant Professor of Surgery Section of Colon & Rectal Surgery Montefiore Medical Center/ Albert Einstein College of Medicine







Introduction

devastating physical disability
 affects self-confidence, personal image
 social isolation, job loss

\$400 million annually in US for adult diapers in 1988

leading cause of nursing home placement


more common than dementia

Definitions

highly variable

"continuous or recurrent uncontrolled passage of fecal material (>10cc) for at least one month, age>3yo"

MINOR INCONTINENCE
 inadvertent release of flatus
 partial soiling with liquid stool
 MAJOR INCONTINENCE
 involuntary excretion of feces



Epidemiology

UNDER-REPORTED


prevalence variable (1-24%)
 11-15% community-dwelling adults
 47% nursing home residents
 depends on definitions
 7% fecal soiling
 0.7% gross incontinence



"...But Kevin, why can't we have a proper jacuzzi like next door?"

only 15-45% of patients will discuss with PMD

Epidemiology



It is estimated that more than 18 million adults in the United States
 – 1 in 12 – suffer from fecal incontinence (FI)⁵

FI is nearly as prevalent as many other chronic diseases and more prevalent than other illnesses well-known to impact many Americans.^{1-4,6-7}

^{1.} Stewart, W.F et al. Prevalence and Burden of Overactive Bladder in the United States. World Jrnl of Urol 2003:20:327-336

^{2.} Serels S. The wet patient: understanding patients with overactive bladder and incontinence. Curr Med Res Opin. 2004;20(6):791-801.

^{3.} Centers for Disease Control and Prevention Website. http://www.cdc.gov/asthma/brfss/03/lifetime/tableL1.htm. Accessed October 18, 2010.

^{4.} National Diabetes Information Clearinghouse Website. http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/#y_people. Accessed October 18, 2010.

^{5.} Whitehead W.E. et al. Fecal Incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009; 137:512-517.


^{6.} National Osteoporosis Foundation Website. http://www.nof.org/node/40. Accessed October 18, 2010.

^{7.} Alzheimer's Association Website. http://www.alz.org/alzheimers_disease_facts_figures.asp. Accessed October 18, 2010.

FI Impacts Quality of Life

Fecal Incontinence Quality of Life Scale (FIQOL) Scores

Note: Higher scores translate to higher quality of life




Medtronic data on file. InterStim Therapy for Bowel Control Prospective Clinical Study. PMA#P080025.

Risk Factors

► AGE (2.6% in twenties \rightarrow 15% older than 70)


- chronic diarrhea
 IBS
 CORD
- COPD
- urinary incontinence
- colectomy
- poor health, physical limitations

multiparity only on univariate analysis
 female gender?? conflicting data...




Pathophysiology





Maintaining Continence

mental function stool volume & consistency colonic transit rectosigmoid peristalsis rectal distensibility rectal compliance anorectal sensation anorectal reflexes pelvic floor function sphincter complex (IAS & EAS)



Anatomic Factors

Rectosigmoid

- antiperistaltic waves
- reflex contraction when large volumes enter sigmoid




Rectum

- valves of Houston, mucosal folds
- can accommodate 300cc without increase in pressure
- over 300cc→URGENCY

Anatomic Factors

Internal Anal Sphincter

- circular smooth muscle
- enteric innervation
- 80-90% of resting anal pressure




External Anal Sphincter & Puborectalis


- striated muscle
- somatic innervation (pudendal, S3-4)
- squeeze pressure \rightarrow double MRAP
- VOLUNTARY CONTINENCE, reflex contraction during cough or lifting

Anatomic Factors


Pelvic Diaphragm




Anorectal Angle



Flap Valve Mechanism




Flutter Valve



Loss of Continence

abnormal stool consistency, overflow reduced storage capacity or compliance abnormal sensation abnormal pelvic floor or sphincter mechanism



MOSTLY MULTIFACTORIAL

Overflow Incontinence

Diarrhea

- IBD, infection, radiation enteritis, short gut
- laxative abuse, dementia

Constipation or Impaction


- IBS, childhood encopresis
- constipating medications
- dementia, psychosis
- immobility, reduced fiber intake
- mainly ELDERLY

Reduced Storage Capacity (decreased compliance)

inflammatory bowel disease rectal ischemia radiation proctitis colitis collagen vascular disease rectal neoplasms absent rectal reservoir ileoanal, LAR

Impaired Rectal Sensation

▶ diabetes mellitus → multifactorial; megarectum ▶ CVA, MS, spinal cord or brain lesion



Abnormal Pelvic Floor Sphincter Defects

Obstetrical Injury

- defects in 35% primiparous & 40% multiparous
- only 1/3 to 1/2 symptomatic \rightarrow immediate or years later
- <u>RISK FACTORS</u> → 3rd 4th degree lacs, prolonged labor, forceps, complications of episiotomy, high birth weight, OP presentation, prior injury or postpartum symptoms

Anorectal Surgery

- fistula operations most common culprit
- also hemorrhoid surgery, tx of fissures

Sultan, NEJM, 1993 Oberwalder, BJS, 2003

Abnormal Pelvic Floor Denervation


Primary—"idiopathic neurogenic incontinence"

- <u>pudendal neuropathy</u> in 80%→ puborectalis & EAS denervated, no voluntary control, no anorectal angle
- descending perineal syndrome→traction neuropathy due to chronic straining, prolonged vaginal delivery
- irreversible injury when nerves stretched as little as 12%

Secondary

- spinal cord or cauda equina injuries
- diabetic neuropathy

Diagnosis



History

etiologic factors
onset, duration, amount, and frequency
type of incontinence
urgency & frequency

SEVERITY

Wexner ScoreWilliams Score



See more funny photos at FUNNYBOX.COM

► **QUALITY OF LIFE** (FIQOL scale)

Wexner Scale

Type of Incontinence	Never	Rarely (<1/month)	Sometimes (<1/week)	Usually (<1/day)	Always (>1/day)
Solid	0	1	2	3	4
Liquid	0	1	2	3	4
Gas	0	1	2	3	4
Requires pad	0	1	2	3	4
Lifestyle alteration	0	1	2	3	4

0 points = perfect continence

20 points = complete incontinence

FIQOL Scale

Scale 1: Lifestyle

I cannot do many of the things I want to do (agreement, 4 points) I am afraid to go out (frequency, 4 points) It is important to plan my schedule (daily activities) aroundmy bowel pattern (frequency, 4 points) I cut down on how much I eat before I go out(frequency, 4 points) It is difficult for me to get out and do things likegoing to a movie or church (frequency, 4 points) I avoid traveling by plane or train (agreement, 4 points) I avoid traveling (frequency, 4 points) I avoid visiting friends (frequency, 4 points) I avoid going out to eat (agreement, 4 points) I avoid staying overnight away from home (frequency, 4 points)

Scale 2: Coping behavior

I have sex less often than I would like to (agreement, 4 points) The possibility of bowel accidents is always on my mind(agreement, 4 points) I feel I have no control over my bowels (frequency, 4 points) Whenever I go somewhere new, I specifically locate where the bathrooms are (agreement, 4 pts) I worry about not being able to get to the toilet in time(frequency, 4 points) I worry about the bowel accidents (agreement, 4 points) I try to prevent bowel accidents by staying very near abathroom (agreement, 4 points) I can't hold my bowel movement long enough to get tothe bathroom (frequency, 4 points) Whenever I am away from home I try to stay near a restroom as much as possible (frequency, 4 pts)

FIQOL Scale

Scale 3: Depression

In general, would you say your health is (excellent–poor 5 points) I am afraid to have sex (agreement, 4 points) I feel different from other people (agreement, 4 points) I enjoy life less (agreement, 4 points) I feel like I am not a healthy person (agreement, 4 points) I feel depressed (agreement, 4 points) During the past month, have you felt so sad, discouraged,hopeless, or had so many problems that you wondered if anything was worthwhile? (extremely so–not at all, 6 points)

Scale 4: Embarrassment

I leak stool without even knowing it (frequency, 4 points) I worry about others smelling stool on me (agreement, 4 points) I feel ashamed (agreement, 4 points)

Physical Exam


External assessment


- odour, use of pad, undergarment soiling
- dermatitis, surgical scars
- hemorrhoids, fistulas, prolapse
- "anal wink"

Digital exam

- mass or fecal impaction
- resting & squeeze pressure
- anovaginal septum, perineal body













length of anal canal maximal resting anal pressure



voluntary functionamplitude & duration of squeeze pressure




rectal sensation & compliance

- rectal sensory threshold
- first sensation of urgency (20cc)
- maximum tolerable volume (sensation of pain)
- biofeedback not helpful if sensory threshold poor..


cannot discriminate between anatomic & neurologic defects

Pudendal Nerve Terminal Latency

▶ evaluates pelvic floor innervation
 ▶ measures time from pudendal stimulation to EAS contraction (normal→2.0 msec)



Pudendal Nerve Terminal Latency



painless but operator dependent
 poor correlation with symptoms & histology


Endoanal Ultrasound

anatomic defects
sphincters
puborectalis
rectal wall

correlates well with manometry
 simple, reliable, non-invasive




Normal anal ultrasound



Anal ultrasound showing the anal sphincter muscles in cross section through the mid anal canal. The darker homogenous ring is the internal anal sphincter smooth muscle (i). The white heterogeneous ring surrounding this is the external anal sphincter (arrows; E). The top of the figure is anterior.




Anterior sphincter damage




Anal ultrasound scan of a woman with anterior sphincter damage due to obstetrical complications. The top of the figure is anterior. There is disruption of the muscles of both the internal anal sphincter (small arrows) and the external anal sphincter (large arrows).



MRI (endoanal or surface coil)





Defecography

radiologic visualization of defecation

- shows pelvic floor activity in each stage → rest, straining, defecation, closing
- changes in anorectal angle
- degree of evacuation
- evaluates pelvic descent
- detects occult or overt prolapse

limited use for incontinencewide inter-observer variability





Management

Medical Therapy

improve stool consistency

- treat underlying cause
- dietary modifications
- bulking agents



constipating medication ->
 loperamide>>diphenoxylate, anticholinergics, codeine, bile acid binders, TCAs, topical neo

perineal hygeine, scheduled toileting
 enemas, colonic irrigation +/- anal plug
 mainly helpful for minor incontinence

Biofeedback

cognitively retraining pelvic floor & abdominal wall musculature using electrodes on an anal plug and abd wall surface


improve striated muscle contraction

- enhance ability to perceive rectal distension
- coordinate pelvic floor contraction with rectal distention

best for partial denervation
 minor structural defects
 non-invasive & cheap time-consuming & labor intensive



Biofeedback



results are mixed (38-100% success rates)

- benefits 75%, cures 50%
- best after anorectal surgery, worst \rightarrow spinal cord injury

Biofeedback

superior to pelvic floor strengthening exercises


deterioration with time

may need refresher sessions

CLINICIAN EXPERTISEPATIENT MOTIVATION


Not helpful for—


- dementia
- complete denervation
- decreased rectal capacity 2° proctitis or resection



Vaginal Insert

approved by FDA in 2015dynamic, patient-controlled, reversible





Vaginal Insert LIFE Study

Multicenter, open-label

110 patients entered study



Vaginal atrophy was relative contraindication

Only 55% properly fitted & continued on

Successful symptom reduction at 1 & 3 mos.
 86% per protocol, 79% intention to treat
 Improved FIQOL, 96% comfortable

LIBERATE (larger, long-term f/u)

Vaginal Insert LIBERATE Study

Multicenter, open-label


- 73 patients eligible to enroll
 - Successful fit required
 - Successful 2 wk trial
 - Baseline mean of 14.1+/-12.15 FI episodes over 2 wks

▶ <u>Primary outcome</u> → success at 3, 6, 12 mos

► Secondary outcomes → FIQL, St. Mark's score, other satisfaction measures




Vaginal Insert LIBERATE Study



Legend: Values displayed are percentages of participants in each group with at least 50% reduction in frequency of FI episodes per 2 week period with 95% Clopper-Pearson confidence intervals; p-values reflect exact binomial test comparing these percentages to 40%.

Richter HE, et al. Female Pelvic Med Reconstr Surg 2019; 25: 113-119

Vaginal Insert LIBERATE Study



Standard Deviation

Richter HE, et al. Female Pelvic Med Reconstr Surg 2019; 25: 113-119

Anal Insert Device



Single use, soft silicone (two upper disk sizes)
 Expels spontaneously with BM

http://renew-medical.com/wp-content/uploads/2015/12/Renew_Medical_IFU_EN_LAB605_RevC.pdf

Anal Insert Device Safety & Efficacy Data


► 73 pts completed 12 weeks of treatment

62% success (ITT)QOL not evaluated

AEs in 51%

- Urgency
- Displacement

Irritation, pain, soreness



Lukacz, ES et al. Dis Col Rectum 2015; 58: 892-8.

Surgical Options

Repair
Reinforce
Replace
Re-innervate





Repair

Anterior Sphincteroplasty


- traumatic sphincter injury
- overlapping repair

restores perineal body, corrects rectovag fistula


Postanal Repair

- pelvic floor weakness or descent
- denervation damage
- restores anorectal angle & lengthens anal canal
- Replaced by SNS

Anterior Sphincteroplasty



Anterior Sphincteroplasty




Anterior Sphincteroplasty

functional improvement in 50-80%
BUT deteriorates over time
most have residual symptoms
can repeat repair

risk factors for poor outcome
 pelvic floor denervation
 residual sphincter defect
 lateral or posterior repairs

Outcome vs. Length of F/u

Halverson & Hull DCR 2002



Reinforce

Anal Encirclement

(Thiersch 1891) *now...*Biologic Mesh??

Muscle Transposition dynamic graciloplasty gluteus maximus transfer

Injectable & Implantable Bulking Agents

SECCA Procedure




Dynamic Graciloplasty

Indications

- completely destroyed sphincter
- defect too large for repair

Technical Issues


- anatomically suitable, expendable adductor function
- must be adapted to contain long-acting, automatic, non-fatiguable muscle fibers
- implanted stimulator device not available in US



Results

- success rates vary 40-80% (73% continence at 2yrs)
- complication rates high but treatable (39% wound infxn)
- median survival of implanted battery \rightarrow 405 weeks


Gluteus Transposition





Gluteus maximus muscle Superior gluteal arteries and nerves

Piriformis muscle Inferior gluteal arteries and nerves Sacrotuberous ligaments

Sciatic nerve








Injectable Bulking Agents
facilitates closure of the anal canal
no change in anal canal pressure
submucosal or intersphincteric injection

- silicone, collagen
- biologic tissue
- carbon-coated microbeads




 some positive short-term results but variable effect on quality of life
 side effects
 bleeding, discharge, pain, pruritis, BM changes, abscesses...

Injectable Bulking Agents

Material	Author, yr	n	f/u (mos.)	Morbidity	Results
PTFE	Shafik 1993	11	18-24	0	63% after 2 nd injection
Autologous fat	Shafik 1997	14	9-24		86% after 2 nd injection
Silicone	Malouf 2001	10	6		30%
Silicone	Tjandra 2004	42 (sono) 40 (RCT)	12	0	more improvement with sono guide
Silicone	Soerensen 2008	33	3-22		18% major improve, no manometry change
Hyaluronic Acid	Graf 2011	136/70 (RCT)	6	128 minor 2 serious	52% treated vs. 31% sham
Hyaluronic Acid	Danielson 2009	34	12	0	mean incontinence episodes reduced 22->10

Long-term Data




112 of the 136 patients with 36 month f/u
 BUT...no specific selection criteria, only 6% complete continence at 6 months

Ratto, et al. Neurogastroenterol Motil 2014; 26: 1087-94

Implantable Bulking Agents "Gatekeeper"

 Polyacrylonitrile cylinder
 Inserted into intersphincteric space
 Four quadrants






C Prosthesis released from sheath




d EUS check for position of prostheses




Ratto, et al. BJS 2011; 98: 1644-1652

Implantable Bulking Agents "Gatekeeper"

pilot study (14 pts)
3 yr mean follow-up
No major morbidity






Ratto, et al. BJS 2011; 98: 1644-1652

Implantable Bulking Agents "Gatekeeper"

Prospective multicenter analysis of 54 pts
Safe and sustained clinical efficacy to 1 yr





Ratto, et al. BJS 2016; 103: 290-9.

Implantable Bulking Agents "SphinKeeper"



10 patients Local anesthetic EUS guided






Ratto, et al. Tech Coloproctol 2016; 20: 59-66

SECCA Procedure

delivery of temperaturecontrolled RF energy to internal sphincter

stimulate collagen deposition & scarring



increase ability to recognize & retain stool

► FDA approved in 2002

SECCA

requires sedationinto internal sphincter




20 sets of lesions from 5mm below to 2cm above dentate line

up to 84% have positive response



Pilot Study (2002)




Indications for use: The Secca[™] System is indicated for the treatment of fecal incontinence in those patients with incontinence to solid or liquid stool at least once per week and who have failed more conservative therapy.

* p<0.05 vs. baseline. Takahashi, et al. ASCRS 2002


CCF-FI = Cleveland Clinic Florida - Fecal Incontinence

Follow-Up Report (2008)

WEXNER SCORE




Diseases of the Colon Takahashi-Monroy, et al. 2008




SECCA randomized data

RCT 40 pts
secca vs. sham
6 month f/u




 Statistically but <u>not clinically</u> significant improvement in incontinence episodes

No change in QOL
 No change in anorectal function



SECCA Summary

safe & well-tolerated minimally invasive "no bridges burned" First-line?? before surgery non-surgical candidates ► after failed procedure last resort prior to colostomy need better efficacy data to inform patient selection




Replace

Artificial Bowel Sphincter

- occlusive fluid-filled cuff encircles anal canal
- pressure-regulating balloon
- control pump in labia

Results

- excellent when it works
- 85% complication rate
- 50% removal
- evacuation difficulty
- pain, infection, erosion into vagina



ABS: Safety & Efficacy Wong et al, DCR 2002

multicenter, prospective

112 patients implanted (age 18-81)




384 device-related adverse events in 99 pts
246 required no or non-invasive intervention
51 pts required 73 revisions (46%)
infection requiring revision in 25%

41 pts required explantation (37%), 7 reimplanted

Adverse Effects

Wong et al, DCR 2002



▶ "other" → anourethral fistula, constipation, cuff too large

ABS: Safety & Efficacy Wong et al, DCR 2002


FI scores improved in 63 pts at 6 mos., 55 pts. at 12 mos.

Successful Outcomes 85% in pts with functioning device 53% intention to treat

for severe FI with significant anatomic deformity and/or denervation


Factors Associated with Failure Wexner, et al., DCR, 2009

▶ 51 procedures in 47 pts → infection in 23 ▶ Cumulative Risk of Explantation (57% at 5 yrs)



► EARLY → h/o perineal sepsis
 ► LATE → device malfunction


Magnetic Anal Sphincter



first described in 2010 (14 pts; 5 pt with 6 mo f/u)
 reduction of weekly incontinence episodes from 7.2 to 0.7 (90.9%)
 reduction in Wexner score from 17.2 to 7.8 (54.7%)


2 pts at 1 yr f/u with perfect continence

Magnetic Anal Sphincter



successful implantation in 94%clinical improvement in 76%


Magnetic Anal Sphincter




increased resting tone & squeeze

Magnetic Anal Sphincter Long-Term Data

prospective multicenter pilot study
 35 pts with severe FI, median follow-up 5 yrs



Magnetic Anal Sphincter Long-Term Data




Compared to SNS? *two RCTs...* SaFaRI (350 pts, UK) + MOS STIC (156 pts, France)

Sugrue, et al. DCR 2017; 60: 87-95

What about Stem Cells?

- placebo-controlled DB RCT
 24 pts, 6 & 12 mos f/u
 intersphincteric injection of autologous myoblasts
- ▶ <u>6 mos</u>→significant improvement in both groups
- ► <u>12 mos</u> → placebo returned to baseline, AM continued to improve

overall response rate--58% vs. 8% (p=0.03)



Re-innervate

Sacral Nerve Stimulation


- effective for urinary incontinence → also improved fecal incontinence in those pts
- for pelvic floor denervation with structural integrity
- first studies in 1995
 popular in Europe
 approved in US
 April 2011





Sacral Nerve Stimulation

electrode inserted into S3 foramen
 low grade stimulation via implanted stimulator

can do 2-3 wk operative trial
 or...3 day office-based test
 permanent->up to 8 yrs







SNS Technique



Sacral Nerve Stimulation How Does It Work?

"Focuses mild electrical pulses on the nerves that control the pelvic floor muscles, anal sphincters,


a * While the precise mechanism of action for InterStim Therapy has
t not been fully established, efficacy
n has been proven in clinical studies...

Kenefick N 90:125

* While the precise mechanism of action for InterStim Therapy has not been fully established, efficacy has been proven in clinical studies.

Sacral Nerve Stimulation

- 80% success rate overall
 - increased rest
 - & squeeze pressure (sometimes)
 - improved rectal sensation)
 - about 40% achieve complete continence




More and more long-term data >10 yrs
 adverse events include...

pain, seroma, infection, vaginal tingling, GI/GU upset

rarely explantation needed

Clinical Efficacy: Reduction in Episodes


InterStim Therapy Bowel Control Study



1. Wexner SD, Coller JA, et al. Ann Surg. 2010 Mar;251(3):441-9.

Meditronic-sporsored research. InterStim Therapy Clinical Summary Insert, 2011.

Clinical Efficacy: Complete Continence




Wexner SD, Coller JA, et al. Ann Surg. 2010 Mar;251(3):441-9.

2. MoStronic-sporsored research. InterStim Therapy Cinical Summary Insert, 2011.


 Tjandra JJ et al. Sacral nove stimulation is more effective than optimal medical therapy for severe feeal incontinence: a randomized, controlled study. Dis Color Rectum. May 2008;51(5):494-502.

Clinical Efficacy: Quality of Life



1.


Six Year Experience



p< 0.001 for 3 and 6 months, and 1, 2, 3, 4 and 6 years. p=0.001 for 5 years


Michelsen et al. DCR 2010

More Long-term Data



Hull, et al. DCR 2013; 56: 234-245.

More Long-term Data



Hull, et al. DCR 2013; 56: 234-245.

Adverse Events

Test Stimulation Phase (n=132)
 implant site pain (3.8%), lead fracture (1.5%)

Implant Phase (n=120)


implant site pain (25.8%), implant site infection (10.5%)

- parasthesias (10.8%), change in sensation of stimulation (5.8%)
- diarrhea (5.8%), pain (5%), urinary incontinence (5%)

Lower rate of infection overall compared to other treatments

► Early →abx...LATE→requires explantation (about 19% at 5 yrs)¹

Rates of re-intervention



Time from implant (in years)

Hull, et al. DCR 2013; 56: 234-245.

What about the more typical FI pts?

Retrospective analysis of all pts undergoing SNS in Finland from 1999-2017

- 462 procedures done for FI→432 pts for analysis
- 313 (72.5%) had successful test phase
 - ► 25% obstetrical injury
 - > 23% iatrogenic injury (LAR, STARR, hem/fistula sx)
 - ▶ 16% neurologic etiologies

Long-term success in 59.3%

- Subjective pt reports & permanent functioning device
- Mean follow-up 2.4 yrs
- Etiology impacted test success but not final outcome

SNS Summary

minimally invasive, broad applicability

comparable or better efficacy with much lower morbidity than other surgical options

Reproducible and durable results

no burnt bridges....first step or last resort, combined approach?

BUT... expensive, MRI incompatibility, need for revision in about 25%

Tibial Nerve Stimulation

Percutaneous or transcutaneous

- L4/5 & S1/2/3 fibers
- motor, sensory, autonomic

First described in 1980s for GU sxs

- 60-80% success rates in case series
- FDA approved in 2000
- RCT of 220 pts (54.5% vs. 20.9% sham)

FDA approved in 2000 (not for FI)

Peters, et al. J Urol 2016; 183: 1438.

Tibial Nerve Stimulation

► In-office procedure Hand-held stimulator ▶ 30 minute sessions Weekly or biweekly for 6-12 wks Test mode to determine appropriate current for motor & sensory response Well-tolerated, rare paresthesias/numbress

Tibial Nerve Stimulation Data for FI

Case series report 59-77% success

► Randomized, Placebo-controlled Trials
 82% PTNS vs. 45% TTNS vs. 13% sham (only 30 pts)¹
 CONFIDENT (115/112 pts)→38% PTNS vs. 31% sham²
 ► Compared to SNS?
 ■ Retrospective data showed no difference³
 ■ Randomized pilot→SNS better (67% vs. 47%)⁴

- 1. George, et al. BJS 2013; 100: 330-8.
- 2. Knowles, et al. Lancet 2015; 386: 1640-8.
- 3. Asari, et al. Colorectal Dis 2014; 16: 0393-99.
- 4. Thin, et al. BJS 2015; 102: 349-58.

or finally...Re-route



converts perineal colostomy to abdominal stoma

when all other treatment fails, BUT address in initial consultation

simplifies bowel care & improves quality of life

combine with <u>rectosigmoid</u> <u>resection</u> to avoid persistent mucus discharge

In Summary

devastating problem which is under-recognized and under-reported

multifactorial etiology

role of diagnostic testing?

many new treatment options, no clear algorithm anymore

minimalist approach over major reconstruction

When 900 years old you reach,

Depend d Briefs

Depend

have control, you will not."

Depen

Fitted Brief

Depend Fitted Briefs

Overnight Demilt Nocturna